PCNA and non-small cell lung carcinoma: Further studies demonstrated that both compounds showed efficacy in cisplatin-resistant non-small cell lung cancer (NSCLC) cells when used in combination with cisplatin, as well as enhanced proliferating cell nuclear antigen (PCNA) and FANCD2 monoubiquitylation in human embryonic kidney 293T (HEK293T) cells.